Zacks: Biotie Therapies Oyj (NASDAQ:BITI) Receives Average Rating of "Strong …

Zacks: Biotie Therapies Oyj (NASDAQ:BITI) Receives Average Rating of "Strong …

1.5kViews

ZIMBABWE – Biotie Therapies Oyj (NASDAQ:BITI) has received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Analysts have set a 1 year consensus price objective of $28.00 for the company and are predicting that the company will post ($0.87) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Biotie Therapies Oyj an industry rank of 61 out of 265 based on the ratings given to its competitors.

Shares of Biotie Therapies Oyj (NASDAQ:BITI) traded down 1.74% on Monday, hitting $14.10. The stock had a trading volume of 3,097 shares. Biotie Therapies Oyj has a 52-week low of $12.43 and a 52-week high of $25.39. The firm’s market cap is $172.87 million. The firm’s 50-day moving average price is $14.10 and its 200 day moving average price is $16.24.

Several research analysts recently commented on the company. Zacks Investment Research cut Biotie Therapies Oyj from a “hold” rating to a “sell” rating in a research note on Monday, October 12th. RBC Capital reissued an “outperform” rating and set a $35.00 target price on shares of Biotie Therapies Oyj in a research note on Monday, September 28th.

Biotie Therapies Oyj is a Finland-based drug development company focused on developing products for neurodegenerative and psychiatric disorders. The Company’s lead market product is Selincro (NASDAQ:BITI), a therapeutic for alcohol dependence that is rolled out across Europe by its partner Lundbeck. Its product pipeline includes tozadenant, a therapeutic for Parkinson’s disease that is in Phase Three development; and two additional compounds in Phase Two development that treat cognitive disorders, namely: SYN120, an orally administered compound therapeutic for Parkinson’s disease dementia, and BTT1023, a human monoclonal antibody targeting compound therapeutic for primary sclerosing cholangitis. The Company operates as a subsidiary of Biotie Therapies Corp.

    love 0 Love
    wink 0 Wink
    lol 0 LoL
    wow 0 Wow
    cry 0 Cry
    angry 0 Angry